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creativecommons.org/licenses/by-nc-nd/3.0/).The administration of intravenous ﬂuid to critically ill patients is
one of the most common but also one of the most ﬁercely
debated interventions in intensive care medicine. During the past
decade, a number of important studies have been published
which provide clinicians with improved knowledge regarding the
timing, the type and the amount of ﬂuid they should give to their
critically ill patients. However, despite the fact that many thou-
sands of patients have been enrolled in these trials of alternative
ﬂuid strategies, consensus remains elusive and practice is widely
variable.
Early adequate resuscitation of patients in shock followed by a
restrictive strategy may be associated with better outcomes. Col-
loids such as modern hydroxyethyl starch are more effective than
crystalloids in early resuscitation of patients in shock, and are safe
when administered during surgery. However, these colloids may
not be beneﬁcial later in the course of intensive care treatment and
should best be avoided in intensive care patients who have a high
risk of developing acute kidney injury. Albumin has no clear
beneﬁt over saline and is associated with increased mortality in
neurotrauma patients. Balanced ﬂuids reduce the risk of hyper-
chloraemic acidosis and possibly kidney injury. The use of hyper-
tonic ﬂuids in patients with sepsis and acute lung injury warrants
further investigation and should be considered experimental at
this stage.nharen@act.gov.au (F. van Haren).
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F. van Haren, K. Zacharowski / Best Practice & Research Clinical Anaesthesiology 28 (2014) 275e283276Fluid therapy impacts relevant patient-related outcomes. Clini-
cians should adopt an individualized strategy based on the clinical
scenario and best available evidence. One size does not ﬁt all.
© 2014 The Authors. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The administration of intravenous ﬂuids is one of the most common interventions in the intensive
care environment. There is ongoing discussion regarding the beneﬁts and disadvantages of infusion
therapy. While the application of ﬂuid during shock leads to circulatory stabilization and can
therefore be life-saving, ﬂuid overload is associated with oedema development and worse outcomes.
This single measure, which may be vital in the early phase of shock, also has the potential to harm the
patient. Interestingly, despite the worldwide use of various infusion solutions, no concrete evidence
has been provided that infusion therapy per se leads to a lower mortality among seriously ill patients.
This may be related to the complexity of treatment in an intrinsically heterogeneous group of crit-
ically ill patients, as well as to considerable differences that exist in the clinical use of infusion
therapy.
In the past 10 years, an impressive amount of new research has been conducted and published in
the ﬁeld of ﬂuid resuscitation in critically ill patients. To put this statement into context, combining the
search terms ﬂuid resuscitation and intensive care in PubMed, and limiting the search to papers
published between 2003 and 2013, an impressive number of 1238 publications can be identiﬁed. The
results of some of the largest and most rigorously conducted studies in the history of intensive care
medicine have provided clinicians with useful answers but also with many more questions and, as a
result, a signiﬁcant level of debate and controversy still remains. In the following review, an attempt
will be made to put some of these new data into clinical context. Some of the more speciﬁc topics (e.g.,
balanced solutions, ﬂuids in trauma and ﬂuids in anaesthesia) will be discussed elsewhere in this
edition of Best Practice and Research, Clinical Anaesthesiology, and readers will be referred to other
sections where appropriate.
Timing of ﬂuid administration
It is important to differentiate between ﬂuid substitution and volume substitution in intensive care
patients [1]. Different indications warrant different strategies and ﬂuid choices, a distinction that has
not always been appreciated sufﬁciently in the design of ﬂuid studies.
The now generally accepted concept based on some interventional but mostly on observational
studies and expert opinion is that resuscitation of patients in shock needs to be timely and adequate.
Often, this part of the resuscitation will have occurred in the pre-intensive care unit (ICU) setting, for
example, in the emergency department.
Early goal-directed treatment (EGDT) of septic shock has been incorporated into the surviving
sepsis guidelines [2,3]. However, the ﬁndings of the original Rivers et al. study were not replicated in
the recently published randomized trial of Protocol-based Care for Early Septic Shock (ProCESS) [4]. In
this study, 1341 patients with septic shock were randomly assigned to protocol-based EGDT, protocol-
based standard therapy or to usual care. Resuscitation strategies differed signiﬁcantly with respect to
the monitoring of central venous pressure and oxygen and the use of intravenous ﬂuids, vasopressors,
inotropes and blood transfusions. No differences in 90 day mortality, 1-year mortality or the need for
organ support were observed.
Other large studies including the Australasian Resuscitation in Sepsis Evaluation randomized
controlled trial (ARISE) and the Protocolised Management in Sepsis trial (ProMISe) are currently under
way and should provide us with more deﬁnitive data in this speciﬁc area of ﬂuid resuscitation [5]. An
important challenge the investigators of these three important trials face is the likelihood that the
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and the subsequent publication of the Surviving Sepsis guidelines.
In the next phase of their treatment, once patients have been stabilized, it has been shown that
a restrictive ﬂuid resuscitation strategy may improve outcome. Fluid-overloading our patients or
causing hypervolaemia in the post-resuscitation phase indeed is likely to be harmful. For example,
in septic shock patients, a positive ﬂuid balance and elevated central venous pressure are associ-
ated with an increased mortality [6]. Patients with a less positive ﬂuid balance tend to have a better
outcome, but this may simply be because these patients are less severely ill and therefore tolerate
this strategy, rather than this being a direct effect of an intervention targeted at a negative ﬂuid
balance. For example, both early adequate resuscitation and restrictive ongoing resuscitation
independently improved outcome in a retrospective cohort of patients with septic shock and acute
lung injury [7].
Rather alarmingly, we as clinicians do not appear to be particularly good at determining whether
a patient will beneﬁt from the administration of a ﬂuid bolus, especially when basing this decision
on clinical examination and static haemodynamic indices such as central venous pressure. In studies
summarized in a review by Michard et al., in 2002, around 50% of patients who received a ﬂuid bolus
based on clinical signs and static haemodynamic measurements turned out to be not ﬂuid
responsive [8]. In other words, the decision-making process to administer a ﬂuid bolus was not
much better than tossing a coin. Another important conclusion based on that observation is that we
may be causing harm in about 50% of our patients who are given a ﬂuid bolus in error.
Fluid resuscitation therefore should ideally be based on dynamic indices of ﬂuid responsive-
ness, such as stroke volume or pulse pressure variation, but the presence of arrhythmias and
spontaneous breathing activity and the use of lung protective ventilation may preclude these
indices from being used [9]. The easy-to-perform passive leg-raising test has been well validated
in situations where these dynamic indices cannot be used reliably in the intensive care environ-
ment [10].
Type of ﬂuid
Currently, there is no evidence from randomized controlled trials that resuscitation with colloids,
instead of crystalloids, reduces the risk of death in patients with trauma or burns or following surgery
[11]. The same statement applies to patients with sepsis [12]. However, it is important to emphasize
that ‘colloid’ is not a homogeneous group of ﬂuids. Signiﬁcant differences exist between different
colloids with regard to haemodynamic effects, side effects and pharmacokinetics. It is also important to
note that in intensive care studies, signiﬁcant heterogeneity exists regarding the primary diagnoses,
patients' responses to the underlying illness and its treatment in a context of complex ICU manage-
ment. Because of this heterogeneity, a treatment may be beneﬁcial to one subgroup of patients while
being harmful to another subgroup [13]. This effect may not become apparent in a study, regardless of
the sample size, unless these subgroups have been well recognized and deﬁned a priori. This is a
common but only recently fully appreciated problem, which complicates intensive care research in
many more ways than previously realized.
Great regional variation exists regarding the use of resuscitation ﬂuids in intensive care pa-
tients [14]. In this observational study, colloids were administered to more patients and during
more resuscitation episodes than were crystalloids. The country in which the patient was being
treated was a major determinant of ﬂuid choice even after adjusting for patient and prescriber
characteristics. Some of these variations may be explained by pharmaco-economic considerations
rather than proven clinical beneﬁts. For example, the use of human albumin in Australia is
signiﬁcantly higher than in many other parts of the world, despite the fact that a large trial
conducted by the Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS
CTG), comparing albumin with normal saline in intensive care patients, showed no beneﬁt of
albumin over saline [15]. Albumin is delivered free of charge to Australian hospitals, whereas
prescribing albumin in most Western European countries is relatively costly and in the latter
situation probably not justiﬁed from a pharmaco-economic perspective given the lack of relevant
clinical beneﬁt.
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into volume therapy and ﬂuid therapy. In the ﬁrst occasion, fast and efﬁcient volume replacement is
paramount and solutions that can reach predeﬁned targets in less time may improve outcome, in
the same way that earlier administration of antibiotics improves outcome in patients with septic
shock [16]. Resuscitation with modern starch solutions has been shown to provide more effective
results in the golden hours of resuscitation (also see the contribution by James (this issue),
principles of resuscitation in trauma and neurotrauma) [17,18]. The colloid controversy will be
discussed in more detail later.
Hypertonic ﬂuids
Small-volume hypertonic ﬂuid resuscitation can provide effective and rapid intravascular volume
resuscitation. Recent data suggest that hypertonic ﬂuid administration in sepsis may have beneﬁcial
effects on the global circulation and the cardiac function that exceed simple intravascular volume
expansion. In addition, hypertonic resuscitation may exert speciﬁc effects on inﬂammatory pathways
and endothelial function that may be beneﬁcial in patients with septic shock and acute lung injury
[19,20]. Whether these observations translate into improved clinical outcomes has not yet been
established, and much more work is required before this experimental approach is to be implemented
into clinical practice [21].
Albumin
The use of albumin showed a worldwide decline following the publication of the much-
debated meta-analysis in the late 1990s suggesting possible but substantial harm associated
with the use of albumin in intensive care patients [22]. Since then and as mentioned earlier, the
large Saline versus Albumin Fluid Evaluation (SAFE) study conducted in almost 7000 patients
showed no beneﬁt of albumin over saline, but also no harm [15]. Some relevant subgroup analyses
deserve to be mentioned. In the a priori deﬁned subgroup of septic patients, albumin adminis-
tration was associated with a non-signiﬁcant trend towards improved survival [23]. This ﬁnding
was not consistent with results from a large observational study, where albumin use in septic
patients was associated with an increase in mortality [24]. Based on the observations from SAFE, a
number of prospective randomized trials have been conducted to shed more light on this topic. A
large Italian multicentre study compared the outcomes of 1818 patients in severe sepsis or septic
shock who were randomized to open-label albumin and crystalloid solution versus crystalloid
solution alone [25]. No differences were found between the two groups with respect to mortality
after 28 or 90 days. French investigators conducted a multicentre study in 794 patients with septic
shock and reported similar ﬁndings, with no differences in relevant outcome parameters including
mortality and sequential organ failure assessment scores (NCT00327704, personal
communication).
The SAFE study also suggested that patients with traumatic brain injury resuscitated with albumin
had a higher mortality rate than those resuscitated with saline. This was conﬁrmed in a post hoc study
of critically ill patients with traumatic brain injury, showing indeed that ﬂuid resuscitation with
albumin was associated with higher mortality rates than was resuscitation with saline, and therefore
should better be avoided in this group of patients [26].
Hydroxyethyl starch
Hydroxyethyl starches (HESs) are the most widely used artiﬁcial colloid solutions in the world [14].
It is important to emphasize that HES is not a homogeneous group of ﬂuids [27]. Signiﬁcant differences
exist between different HES formulations, not only regarding molecular weight and the degree of
molar substitution with hydroxyleethyl groups but also with respect to the source material (corn or
potato) and the carrier solution. These differences may translate into different haemodynamic effects,
side effects, pharmacokinetics and thus clinical outcomes.
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patients. However, studies that showed this possible increase in AKI had confounding factors including
the use of older HES products and hyperoncotic solutions, dehydration, excessive HES dose (over-
dosing) and baseline imbalances [28,29]. In a large European prospective observational study, no as-
sociation was found between HES administration and adverse renal events [30]. Because of this
controversy, a number of large-scale trials were undertaken to evaluate the efﬁcacy and safety of
commonly used HES preparations.
In a Scandinavian multicentre study (6S study) with a blinded, parallel group study design, 804
patients with severe sepsis were randomized to ﬂuid resuscitation with potato-derived 6% HES 130/
0.42 (Tetraspan 6%, B. Braun) or Ringer's acetate in a dosage of up to 33 ml/kg ideal body weight/day
[31]. Patients assigned to ﬂuid resuscitationwith HES 130/0.42 had an increased risk of death at day 90
and were more likely to require renal replacement therapy, as compared with those receiving Ringer's
acetate. There was no difference in the rate of end-stage kidney failure (dialysis dependence) at 90
days. Intriguingly, based on reported values of central venous pressure, central venous oxygen satu-
ration and lactate concentration, it appears that most patients were haemodynamically stable at the
time of inclusion in the study. Trial ﬂuid was used when ICU clinicians judged that volume expansion
was needed in the ICU and was not based on protocolled assessment of the haemodynamic situation.
The criteria for renal replacement therapy were also not included in the protocol. Of note, both arms of
the study received different ﬂuid volumes before randomization was carried out. The HES group was
infused with more volume and, on average, one additional blood product than the Ringer's acetate
group.
In the largest intensive care trial to date, the Crystalloid versus Hydroxyethyl Starch Trial (CHEST),
7000 ICU patients were randomly assigned to receive either 6% maize-based 130/0.4HES (Voluven,
Fresenius Kabi) in 0.9% sodium chloride or 0.9% sodium chloride (saline, Fresenius Kabi) for all ﬂuid
resuscitation until ICU discharge, death or 90 days after randomization [32]. There was no signiﬁcant
difference in 90 day mortality (primary outcome) between the two groups. There was also no differ-
ence in mortality between treatment arms in any of the predeﬁned subgroups including the subgroup
of patients with sepsis. Of note, this sepsis subgroup consisted of almost 2000 patients, which is
signiﬁcantly more than the total number of patients in the 6S study. There are several possible ex-
planations why CHEST did not ﬁnd an increase in mortality in patients with sepsis when treated with
HES as opposed to 6S. These include the fact that the mortality of patients with sepsis was lower in
CHEST compared with 6S, and the use of a different HES product with possibly different biological and
pharmacokinetic effects [27].
CHEST also showed that renal replacement therapy was usedmore frequently in the HES group (7%)
than in the saline group (6%) (p ¼ 0.04; p ¼ 0.05 after adjustment for covariates). The duration of
treatment with kidney replacement therapywas comparable in both groups (HES 5.6 days vs. saline 5.5
days, p ¼ 0.86). Interestingly, renal risk (RIFLE-R) and renal injury (RIFLEeI) were observed more
frequently in the saline group than in the HES group. There was no statistical difference in kidney
failure (RIFLE-F) between the groups and there was no loss of kidney function or end-stage renal
disease (RIFLE-L and RIFLE-E).
Meybohm et al. re-evaluated 11 available colloid versus crystalloid studies conducted between
2008 and 2013 including CHEST and 6S, using six criteria to construct a deﬁnition of ‘presumably
correct indication’: short time interval from shock to randomization (<6 h), restricted use for initial
volume resuscitation, use of any consistent algorithm for haemodynamic stabilization, reproducible
indicators of hypovolaemia, maximum dose of HES and exclusion of patients with pre-existing renal
failure or renal replacement therapy [33]. They concluded that the studies showed signiﬁcant het-
erogeneity with regard to these criteria. Therefore, the studies do not answer the question whether
or not HES may be beneﬁcial or harmful when it is limited to immediate haemodynamic
stabilization.
The only study to compare colloids and crystalloids in patients who required resuscitation for
shock was the Colloids Versus Crystalloids for the Resuscitation of the Critically Ill (CRISTAL) study
[34]. CRISTAL was a pragmatic trial comparing crystalloids with colloids for adults in acute hypo-
volemic shock at 57 ICUs across three continents. The study was terminated based on a predeﬁned
stopping rule after 2857 of the planned 3010 patients had been enrolled. Patients treated with
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at 28 days (359 deaths (25.4%) among 1414 colloid-treated patients vs. 390 deaths (27.0%) among
1443 crystalloid-treated patients); however, the colloid group had more days free of vasopressor
therapy and mechanical ventilation at 7 and 28 days and had signiﬁcantly lower mortality at 90 days
(30.7% of colloid group vs. 34.2% of crystalloids group). Other secondary outcomes, including
measures of renal function, did not differ and there were no signiﬁcant treatments by strata effects.
Some possible study limitations need to be mentioned. The study only compared the two classes
(colloid or crystalloid) of ﬂuids, and not any speciﬁc agent. Lack of blinding leaves the study open to
potential bias, although during the entire period of ICU ﬂuid management was nicely separated into
crystalloids or colloids.
This study shows that colloids have a possible advantage over crystalloids when used for initial
haemodynamic stabilization of critically ill patients. This advantage has also been shown in pa-
tients with penetrating trauma [17]. Resuscitation of trauma patients will be discussed in more
detail elsewhere in this edition of Best Practice and Research, Clinical Anaesthesiology by
M. James.
Finally, it is essential to emphasize that the results of the aforementioned intensive care studies
comparing colloids and crystalloids should not be extrapolated to other clinical scenarios. Importantly,
the safety of tetrastarches during surgery has been conﬁrmed in a recent meta-analysis of 59 studies
that randomly allocated 4529 patients with 2139 patients treatedwith tetrastarch comparedwith 2390
patients treated with a comparator [35]. There were no indications that the use of tetrastarches during
surgery induces adverse renal effects as assessed by change or absolute concentrations of serum
creatinine or need for renal replacement therapy, increased blood loss, allogeneic erythrocyte trans-
fusion or increased mortality (odds ratio for HES mortality ¼ 0.51 (0.24e1.05), p ¼ 0.079). In another
meta-analysis of 1230 patients in 17 studies, the effect of maize-derived HES 130/0.4 on renal function
in surgical patients was investigated [36]. No differences were found regarding peak creatinine levels
or need for renal replacement therapy.Balanced ﬂuids
Balanced ﬂuids are crystalloid and colloid solutions with a more physiologically balanced elec-
trolyte formulation, such as Hartmann's solution, PlasmaLyte and Hextend. The use of these ﬂuids
for volume resuscitation can prevent the development of hyperchloraemic acidosis, an electrolyte
abnormality often encountered with the use of ‘normal’ saline even after relatively low-volume
application [37]. In experimental sepsis models, balanced ﬂuids are associated with a better
short-term survival [38]. In a prospective, open-label, sequential period pilot study of 1533 critically
ill patients, the implementation of a chloride-restrictive strategy in a tertiary ICU was associated
with a signiﬁcant decrease in the incidence of AKI and the use of renal replacement therapy [39].
Magder discusses this topic in more detail elsewhere in this edition of Best Practice and Research,
Clinical Anaesthesiology.
Conclusions
Fluid resuscitation is one of the cornerstones of intensive care treatment. The past decade has
provided exciting new research ﬁndings to help clinicians decide when, what and howmuch ﬂuid they
should give to their critically ill patients. Early adequate resuscitation followed by a restrictive strategy
may be associated with better outcomes. Although much controversy remains regarding the type of
ﬂuid that should be used, clinicians should adopt an individualized strategy based on the clinical
scenario. Colloids such as modern hydroxyethyl starch are more effective than crystalloids in the early
resuscitation of patients in shock and are safe when administered during surgery. However, these
colloids may not be beneﬁcial later in the course of intensive care treatment. Albumin has no clear
beneﬁt over saline and is associated with increased mortality in neurotrauma patients. The use of
hypertonic ﬂuids in patients with sepsis warrants further investigation and should be considered
experimental at this stage.
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None.Research agenda
 More work is needed to understand the different effects and side effects (including renal
effects) of different modern HES products, specifically between potato-based and maize-
based products.
 Future volume therapy studies should take into account well-defined criteria for correct in-
dications for fluid administration, including the use of a consistent algorithm for haemody-
namic stabilization and reproducible indicators of hypovolaemia.
 We need to investigate further whether the use of hypertonic fluids improves relevant
patient-related outcomes in sepsis and acute lung injury.
 There is an ongoing need for relevant basic research into the physiology of fluid adminis-
tration (e.g., bolus vs. continuous infusion vs. no fluid resuscitation), as well as into the
in vitro and in vivo effects of different compositions of fluids (e.g., chloride level, tonicity and
strong ion difference).
Practice points
 Fluid strategy for intensive care patients should be individualized and based on the clinical
scenario.
 The timing, the type and the amount of fluid given to critically ill patients have an impact on
relevant patient outcomes.
 Based on best available but not high-quality evidence, early adequate resuscitation followed
by a restrictive fluid strategy provides the best outcomes for critically ill patients.
 There is no clear role for the use of albumin as resuscitation fluid in ICU patients. This is
based on evidence of lack of benefit (as opposed to lack of evidence of benefit), as well as
because of an unfavourable pharmaco-economical balance.
 The use of colloids for resuscitation of patients in shock provides more timely shock reversal
and could possibly improve outcomes.
 Modern HES can be safely used during surgery, but should be avoided in intensive care
patients who have already been resuscitated, specifically in patients who have a high risk of
developing acute kidney injury.References
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